Community-acquired pneumonia and tuberculosis: DIFFERENTIAL diagnosis and the use of fluoroquinolones

International Journal of Infectious Diseases

Volumn 18, Issue 1, 2014, Pages 14-21

  Grossman, Ronald F ^a   Hsueh, Po Ren ^b   Gillespie, Stephen H ^c   Blasi, Francesco ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Differential diagnosis; Fluoroquinolone; Mycobacterium tuberculosis; Pneumonia; Resistance; Tuberculosis

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAPENTINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; DIFFERENTIAL DIAGNOSIS; DRUG USE; HUMAN; LUNG TUBERCULOSIS; MONOTHERAPY; REVIEW; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

DIFFERENTIAL DIAGNOSIS; FLUOROQUINOLONE; MYCOBACTERIUM TUBERCULOSIS; PNEUMONIA; RESISTANCE; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PNEUMONIA; PREVALENCE; TUBERCULOSIS;

EID: 84891557923     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.09.013     Document Type: Review

References (86)

1. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
2. Woodhead M., Blasi F., Ewig S., Garau J., Huchon G., Ieven M., et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011, 17(Suppl 6):E1-E59.
3. Burman W.J., Goldberg S., Johnson J.L., Muzanye G., Engle M., Mosher A.W., et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006, 174:331-338.
4. Dorman S.E., Johnson J.L., Goldberg S., Muzanye G., Padayatchi N., Bozeman L., et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009, 180:273-280.
5. Conde M.B., Efron A., Loredo C., De Souza G.R., Graça N.P., Cezar M.C., et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-1189.
6. Fouad M., Gallagher J.C. Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis. Ann Pharmacother 2011, 45:1439-1444.
7. Singh A. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity. Clin Infect Dis 2007, 45:133. author reply 134-5.
8. Kim S.Y., Yim J.J., Park J.S., Park S.S., Heo E.H., Lee C.H., et al. Clinical effects of gemifloxacin on the delay of tuberculosis treatment. J Korean Med Sci 2013, 28:378-382.
9. Cillóniz C., Ewig S., Polverino E., Marcos M.A., Esquinas C., Gabarrús A., et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011, 66:340-346.
10. Soman A., Honeybourne D., Andrews J., Jevons G., Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999, 44:835-838.
11. Blondeau J.M., Laskowski R., Bjarnason J., Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000, 14:45-50.
12. Leroy O., Santré C., Beuscart C., Georges H., Guery B., Jacquier J.M., et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995, 21:24-31.
13. Vardakas K.Z., Siempos I.I., Grammatikos A., Athanassa Z., Korbila I.P., Falagas M.E. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. Can Med Assoc J 2008, 179:1269-1277.
14. Finch R., Schurmann D., Collins O., Kubin R., McGivern J., Bobbaers H., et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002, 46:1746-1754.
15. Asadi L., Sligl W.I., Eurich D.T., Colmers I.N., Tjosvold L., Marrie T.J., et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012, 55:371-380.
16. Menendez R., Torres A., Zalacaín R., Aspa J., Martín-Villasclaras J.J., Borderías L., et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005, 172:757-762.
17. Migliori G.B., Langendam M.W., D'Ambrosio L., Centis R., Blasi F., Huitric E., et al. Protecting the tuberculosis drug pipeline: stating the case for rational use of fluoroquinolones. Eur Respir J 2012, 40:814-822.
18. Shen G.H., Tsao T.C., Kao S.J., Lee J.J., Chen Y.H., Hsieh, et al. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents 2012, 39:201-205.
19. Nyamande K., Lalloo U.G., John M. TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence. Int J Tuberc Lung Dis 2007, 11:1308-1313.
20. Vray M., Germani Y., Chan S., Duc N.H., Sar B., Sarr F.D., et al. Clinical features and etiology of pneumonia in acid-fast bacillus sputum smear-negative HIV-infected patients hospitalized in Asia and Africa. AIDS 2008, 22:1323-1332.
21. Hopstaken R.M., Muris J.W., Knottnerus J.A., Kester A.D., Rinkens P.E., Dinant G.J. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br J Gen Pract 2003, 53:358-364.
22. Feldman C., Brink A.J., Richards G.A., Maartens G., Bateman E.D. Management of community-acquired pneumonia in adults. South Afr J Epidemiol Infect 2008, 23:31-42.
23. Guidelines for the programmatic management of drug-resistant tuberculosis-emergency update 2008 2008, World Health Organization, World Health Organization, Geneva.
24. Caminero JA. Guidelines for the Clinical and operational management of drug-resistant tuberculosis. Paris, France: International Union Against Tuberculosis and Lung Disease; 2013. Available at: (accessed June 11, 2013). http://www.theunion.org/index.php/en/resources/technical-publications/tuberculosis/item/2363-guidelines-for-the-clinical-and-operational-management-of-drug-resistant-tuberculosis.
25. Ziganshina L.E., Squire S.B. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008, (1):CD004795.
26. ClinicalTrials.gov. Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis (REMoxTB). Available at: (accessed July 9, 2012). http://clinicaltrials.gov/ct2/show/NCT00864383.
27. Pan African Clinical Trials Registry. PACTR201110000124315. Available at: (accessed November 07, 2013). http://www.pactr.org/ATMWeb/appmanager/atm/atmregistry%3Fda=true%26tno=PACTR201110000124315.
28. th Conference on Retroviruses and Opportunistic Infections March 2013.
29. ClinicalTrials.gov. A controlled trial of a 4-month quinolone-containing regimen for the treatment of pulmonary tuberculosis. Available at: (accessed July 9, 2012). http://clinicaltrials.gov/ct2/show/NCT00216385.
30. Halm E.A., Fine M.J., Marrie T.J., Coley C.M., Kapoor W.N., Obrosky D.S., et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998, 279:1452-1457.
31. Menendez R., Torres A., Rodriguez de Castro F., Zalacain R., Aspa J., Martin Villasclaras J.J., et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004, 39:1783-1790.
32. Jaoude P, Badlam J, Anandam A, El-Solh AA. A comparison between time to clinical stability in community-acquired aspiration pneumonia and community-acquired pneumonia. Intern Emerg Med 2012. Epub ahead of print. doi:10.1007/s11739-012-0764-2.
33. Kiblawi S.S., Jay S.J., Stonehill R.B., Norton J. Fever response of patients on therapy for pulmonary tuberculosis. Am Rev Respir Dis 1981, 123:20-24.
34. Mittl R.L., Schwab R.J., Duchin J.S., Goin J.E., Albeida S.M., Miller W.T. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med 1994, 149:630-635.
35. Treatment of tuberculosis: guidelines 2010, World Health Organization, WHO, Geneva. 4th ed.
36. Barlow P.B. Basics of tuberculosis 1976, 1-6. American Thoracic Society. R.G. Louden (Ed.).
37. Bobrowitz I.D. Reversible roentgenographic progression in the initial treatment of pulmonary tuberculosis. Am Rev Respir Dis 1980, 121:735-742.
38. Liam C.K., Pang Y.K., Poosparajah S. Pulmonary tuberculosis presenting as community-acquired pneumonia. Respirology 2006, 11:786-792.
39. Pai M., Zwerling A., Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184.
40. Wang L., Turner M.O., Elwood R.K., Schulzer M., FitzGerald J.M. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax 2002, 57:804-809.
41. Brodie D., Schluger N.W. The diagnosis of tuberculosis. Clin Chest Med 2005, 26:247-271. vi.
42. Pinto L.M., Grenier J., Schumacher S.G., Denkinger C.M., Steingart K.R., Pai M. Immunodiagnosis of tuberculosis: state of the art. Med Princ Pract 2012, 21:4-13. 10.1159/000331583.
43. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement 2011, World Health Organization, WHO, Geneva.
44. Steingart K.R., Henry M., Ng V., Laal S., Hopewell P.C., Ramsay A., et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 2007, 4:e202. 10.1371/journal.pmed.0040202.
45. Steingart K.R., Henry M., Ng V., Hopewell P.C., Ramsay A., Cunningham J., et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006, 6:570-581.
46. Finch D., Beaty C.D. The utility of a single sputum specimen in the diagnosis of tuberculosis. Comparison between HIV-infected and non-HIV-infected patients. Chest 1997, 111:1174-1179.
47. Al Zahrani K., Al Jahdali H., Poirier L., René P., Menzies D. Yield of smear, culture and amplification tests from repeated sputum induction for the diagnosis of pulmonary tuberculosis. Int J Tuberc Lung Dis 2001, 5:855-860.
48. McWilliams T., Wells A.U., Harrison A.C., Lindstrom S., Cameron R.J., Foskin E. Induced sputum and bronchoscopy in the diagnosis of pulmonary tuberculosis. Thorax 2002, 57:1010-1014.
49. Steingart K.R., Sohn H., Schiller I., Kloda L.A., Boehme C.C., Pai M., et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013, (1):CD009593.
50. Lawn S.D., Brooks S.V., Kranzer K., Nicol M.P., Whitelaw A., Vogt M., et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011, 8:e1001067. 10.1371/journal.pmed.1001.
51. Scott L.E., McCarthy K., Gous N., Nduna M., Van Rie A., Sanne I., et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011, 8:e1001061. 10.1371/journal.pmed.1001061.
52. Boehme C.C., Nicol M.P., Nabeta P., Michael J.S., Gotuzzo E., Tahirli R., et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011, 377:1495-1505.
53. Schleicher G.K., Herbert V., Brink A., Martin S., Maraj R., Galpin J.S., et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 2005, 25:688-692.
54. Nyamande K., Lalloo U.G. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 2006, 10:1510-1515.
55. Kang Y.A., Kwon S.Y., Yoon H.I., Lee J.H., Lee C.T. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med 2009, 24:337-342.
56. Ugajin M., Miwa S., Shirai M., Ohba H., Eifuku T., Nakamura H., et al. Usefulness of serum procalcitonin levels in pulmonary tuberculosis. Eur Respir J 2011, 37:371-375.
57. Yoon N.B., Son C., Um S.J. Role of the neutrophil-lymphocyte count ratio in the differential diagnosis between pulmonary tuberculosis and bacterial community-acquired pneumonia. Ann Lab Med 2013, 33:105-110.
58. Minion J., Leung E., Talbot E., Dheda K., Pai M., Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J 2011, 38:1398-1405.
59. Lange C., Mori T. Advances in the diagnosis of tuberculosis. Respirology 2010, 15:220-240.
60. Rao V.K., Iademarco E.P., Fraser V.J., Kollef M.H. Delays in the suspicion and treatment of tuberculosis among hospitalized patients. Ann Intern Med 1999, 130:404-411.
61. Dooley K.E., Golub J., Goes F.S., Merz W.G., Sterling T.R. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002, 34:1607-1612.
62. Chang K.C., Leung C.C., Yew W.W., Lau T.Y., Leung W.M., Tam C.M., et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?. Eur Respir J 2010, 35:606-613.
63. Wang J.Y., Hsueh P.R., Jan I.S., Lee L.N., Liaw Y.S., Yang P.C., et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006, 61:903-908.
64. Golub J.E., Bur S., Cronin W.A., Gange S., Sterling T.R., Oden B., et al. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2005, 9:392-397.
65. Yoon Y.S., Lee H.J., Yoon H.I., Yoo C.G., Kim Y.W., Han S.K., et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005, 9:1215-1219.
66. Chen T.C., Lu P.L., Lin C.Y., Lin W.R., Chen Y.H. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2011, 15:e211-e216.
67. Wang M., Fitzgerald J.M., Richardson K., Marra C.A., Cook V.J., Hajek J., et al. Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic?. Int J Tuberc Lung Dis 2011, 15:1062-1068.
68. Craig S.E., Bettinson H., Sabin C.A., Gillespie S.H., Lipman M.C. Think TB! Is the diagnosis of pulmonary tuberculosis delayed by the use of antibiotics?. Int J Tuberc Lung Dis 2009, 13:208-213.
69. Jeon C.Y., Calver A.D., Victor T.C., Warren R.M., Shin S.S., Murray M.B. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Int J Tuberc Lung Dis 2011, 15:77-83.
70. Gaba P.D., Haley C., Griffin M.R., Mitchel E., Warkentin J., Holt E., et al. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007, 167:2317-2322.
71. Ginsburg A.S., Hooper N., Parrish N., Dooley K.E., Dorman S.E., Booth J., et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003, 37:1448-1452.
72. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537-544.
73. Zhang Y., Yew W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009, 13:1320-1330.
74. Malik S., Willby M., Sikes D., Tsodikov O.V., Posey J.E. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 2012, 7:e39754. 10.1371/journal.pone.0039754.
75. Hegde S.S., Vetting M.W., Roderick S.L., Mitchenall L.A., Maxwell A., Takiff H.E., et al. A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 2005, 308:1480-1483.
76. Migliori G.B., Dheda K., Centis R., Mwaba P., Bates M., O'Grady J., et al. Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on Sub-Saharan Africa. Trop Med Int Health 2010, 15:1052-1066.
77. Yao S., Huang W.H., van den Hof S., Yang S.M., Wang X.L., Chen W., et al. Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in mountainous areas of China. BMC Health Serv Res 2011, 11:341.
78. Problems of multidrug- and extensively drug-resistant TB. Drug Ther Bull 2012, 50:21-24.
79. Shennan D.H. Resistance of tubercle bacilli to isoniazid, PAS and streptomycin, related to history of previous treatment. Tubercle 1964, 45:1-6.
80. Sullivan E.A., Kreiswirth B.N., Palumbo L., Kapur V., Musser J.M., Ebrahimzadeh A., et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995, 345:1148-1150.
81. Devasia R.A., Blackman A., Gebretsadik T., Griffin M., Shintani A., May C., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009, 180:365-370.
82. Long R., Chong H., Hoeppner V., Shanmuganathan H., Kowalewska-Grochowska K., Shandro C., et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009, 48:1354-1360.
83. Park I.N., Hong S.B., Oh Y.M., Lim C.M., Lee S.D., Lew W.J., et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007, 11:319-324.
84. Wang J.Y., Lee L.N., Lai H.C., Wang S.K., Jan I.S., Yu C.J., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007, 59:860-865.
85. Ershova J.V., Kurbatova E.V., Moonan P.K., Cegielski J.P. Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis 2012, 55:1600-1607.
86. Van der Heijden Y.F., Maruri F., Blackman A., Holt E., Warkentin J.V., Shepherd B.E., et al. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. Int J Tuberc Lung Dis 2012, 16:1162-1167.